Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Amcasertib |
Synonyms | |
Therapy Description |
Amcasertib (BBI503) is a kinase inhibitor that inhibits signaling pathways that regulate survival of cancer stem cells, resulting in decreased cancer cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Amcasertib | BBI-503|BBI503 | Amcasertib (BBI503) is a kinase inhibitor that inhibits signaling pathways that regulate survival of cancer stem cells, resulting in decreased cancer cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02232620 | Phase II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | Terminated | CAN | 0 |
NCT02432326 | Phase I | Amcasertib Napabucasin | A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01781455 | Phase Ib/II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Completed | USA | CAN | 0 |
NCT02232633 | Phase II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Completed | CAN | 0 |
NCT02432690 | Phase II | Amcasertib | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | Terminated | USA | 0 |